Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB – Get Free Report)’s share price passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.00 and traded as high as $0.39. Hemispherx BioPharma shares last traded at $0.38, with a volume of 180,482 shares changing hands.
Hemispherx BioPharma Trading Up 6.5 %
About Hemispherx BioPharma
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
See Also
- Five stocks we like better than Hemispherx BioPharma
- How to Most Effectively Use the MarketBeat Earnings Screener
- AbbVie Stock: A Perfect Dip for Investors to Buy
- How to Read Stock Charts for Beginners
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- GitLab Stock Rebounds: The Inside Story of Its Comeback
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.